Benzathine Penicillin G is a formulation of two penicillin G molecules. Benzathine Penicillin G is a treatment used for various bacterial infections such as bejel, diphtheria, rheumatic fever, and also syphilis a sexually transmitted infection caused by the Treponema pallidum bacteria. Benzathine Penicillin G is also used to treat respiratory infections caused due to bacteria and viruses. It functions by inhibiting the growth of bacterial and viral infections in the human body. The key factors responsible for causing bacterial and viral infections are decrease in immunity due to change in lifestyle and having unhygienic food and other which supports the growth of the Benzathine Penicillin G market. According to the Centers for Disease Control and Prevention, December 2015, 21.2 million women of the age group of 14 to 49 years were affected by the bacterial vaginosis infection in the US. Such a high prevalence of bacterial infection can influence the market positively.
However, factors such as allergies and side effects associated with treatments are expected to restrict the market growth during the forecast period.
The Benzathine Penicillin G market is segmented on the basis of application, mode of injection, and end user. The Benzathine Penicillin G market, by the application, is segmented into bacterial infections and sexually transmitted infection (STI) syphilis treatment. Bacterial infections are further segmented into Bejel, diphtheria, and rheumatic fever.
On the basis of mode of injection, the market is segmented into intravenous and intramuscular injection. On the basis of the end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.
On the basis of region, the Benzathine Penicillin G market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Some of the key players in the Benzathine Penicillin G market are Pfizer Inc, Alembic IT Department, ECPlaza Network Inc, Abcam plc, Sandoz International GmbH, Merck KGaA, Triveni Interchem Private Limited, CSC Pharmaceuticals, and others.
Regional Market Summary
Benzathine Penicillin G Market Share (%), by Region, 2017
Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health
It is estimated that North America dominated the Benzathine Penicillin G market owing to the increasing bacterial infection, innovations in clinical practice, bacterial research, and access to viral and bacterial infection treatments in this region. According to the Centers for Disease Control and Prevention 27,814 cases of syphilis, a sexually transmitted infection was reported in the US in 2016. Such a high number of bacterial infection cases in this region influences the market growth in this region.
Europe stood the second largest in the Benzathine Penicillin G market owing to the increasing cases of rheumatic fever. According to the European Centre for Disease Prevention and Control (ECDC), June 2017, 850 000 cases of infectious diseases were notified in Europe in 2014. This number of cases is expected to increase during the forecast period. Such a high incidence rate of infectious diseases supports the growth of the Benzathine Penicillin G market in this region.
Asia-Pacific was estimated to be the fastest growing region for the Benzathine Penicillin G market in 2017. The market is expected to witness growth owing to the rising prevalence of bacterial infection, increasing cases of respiratory infections, and changing lifestyle.
The Middle East and Africa holds the least share in the Benzathine Penicillin G market due to the presence of low health expenditure and low awareness of therapeutic treatments. However, the market is expected to witness growth due to increasing healthcare programs and an increase in investments in research and development in this region.
Market Segmentation and Key Market Players
Benzathine Penicillin G Market, by Therapeutic Use
Benzathine Penicillin G Market, by Mode of Injection
Benzathine Penicillin G Market, by End User
Benzathine Penicillin G Market, by Region
|Market Size||2027: Significant Value|
|CAGR||2020-2027: Substantial CAGR|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Application, Mode of injection, and End user|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Pfizer Inc, Alembic IT Department, ECPlaza Network Inc, Abcam plc, Sandoz International GmbH, Merck KGaA, Triveni Interchem Private Limited, CSC Pharmaceuticals, and others.|
|Key Market Opportunities||High prevalence of bacterial infection|
|Key Market Drivers||
The Americas is expected to dominate the benzathine penicillin G market.
Key competitors in the benzathine penicillin G market include CSC Pharmaceuticals, Triveni Interchem Private Limited, Merck KGaA, Sandoz International GmbH, ECPlaza Network Inc, Alembic IT Department, Pfizer Inc, and Abcam plc.
Different strategies used by market players to create a dominance in the benzathine penicillin G market include mergers, collaborations, acquisitions, and product launches.
Rising prevalence of respiratory infections and sedentary lifestyle are adding market growth.
Side effects and lack of awareness may limit market growth.